Top

Published in:

01-12-2021 | Systemic Lupus Erythematosus | Observational Research

COVID-19 from a rheumatology perspective: bibliometric and altmetric analysis

Authors: Bohdana Doskaliuk, Roman Yatsyshyn, Iryna Klishch, Olena Zimba

Published in: Rheumatology International | Issue 12/2021

Abstract

The Coronavirus disease 2019 (COVID-19) outbreak turned out the greatest pandemic for decades. It challenged enormously the global health system, forcing it to adjust to the new realities. We aimed to analyze articles covering COVID-19 papers in the rheumatological field and outline emerging topics raising within this frame. We applied the bibliometric database Scopus for our literature search and conducted it on the 5th of June using the following keywords: “rheumatic” OR “rheumatology” OR “rheumatoid arthritis” OR “systemic lupus erythematosus” OR “myositis” OR “systemic sclerosis” OR “vasculitis” OR “arthritis” OR “ankylosing spondylitis” AND “COVID-19”. We analyzed all selected articles according to various aspects: type of document, authorship, journal, citations score, rheumatology field, country of origin, language, and keywords. With the help of the software tool VOSviewer version 1.6.15, we have built the visualizing network of authors and keywords co-occurrence. The measurement of the social impact of articles was made using Altmetric data. This study included 1430 retrieved articles with open access mostly. The top five journals in this field were Annals of the Rheumatic Diseases (n = 65), Rheumatology International (n = 51), Clinical Rheumatology (n = 50), Lancet Rheumatology (n = 50), and Frontiers In Immunology (n = 33). Most studies originate from countries with a high incidence of COVID-19 among the general population (the USA—387; Italy—268; UK—184; France—114; Germany—110; India—98 and Spain—96, China—94, Canada—73 Turkey—66). Original Articles (42.1%) were the most common articles’ type, following by Letters (24.4%), Reviews (21.7%), Notes (6%), Editorials (4.8%), Erratum (1%). According to the citations scores, articles dedicated to the clinical course of COVID-19 in patients with rheumatic diseases were of the highest importance for the scientific rheumatologic community. Rheumatoid arthritis (n = 527), systemic lupus erythematosus (n = 393), vasculitis (n = 267), myositis (n = 71), systemic sclerosis (n = 68), and psoriatic arthritis (n = 68) were the most widely discussed rheumatic diseases in the view of COVID-19. The analysis of Altmetric and citations scores revealed a moderate correlation between them. This article provides a comprehensive bibliometric and altmetric analysis of COVID-19 related articles in the rheumatology field and summarizes data about features of rheumatology service in the time of the pandemic.

Pfefferbaum B, North CS (2020) Mental health and the COVID-19 pandemic. N Engl J Med 383(6):510–512. https://doi.org/10.1056/NEJMp2008017CrossRefPubMed

Gupta L, Gasparyan AY, Misra DP, Agarwal V, Zimba O, Yessirkepov M (2020) Information and misinformation on COVID-19: a cross-sectional survey study. J Korean Med Sci 35(27):e256. https://doi.org/10.3346/jkms.2020.35.e256CrossRefPubMedPubMedCentral

Akyol A, Kocyigit BF (2021) Publication activity in the field of Sjögren’s syndrome: a ten-year Web of Science-based analysis. Rheumatol Int 41(4):763–769. https://doi.org/10.1007/s00296-020-04714-1CrossRefPubMed

Akyol A, Kocyigit BF (2021) Ankylosing spondylitis rehabilitation publications and the global productivity: a Web of Science-based bibliometric analysis (2000–2019). Rheumatol Int. https://doi.org/10.1007/s00296-021-04836-0CrossRefPubMedPubMedCentral

Ren W, Liao Y (2021) Visualization analysis of traumatic osteoarthritis research hotspots and content based on CiteSpace. Chin J Tissue Eng Res 25(21):3374

El Masri D, Alsaayed B, El Masri J, Zreika B, Chanbour H, Salameh P (2021) Contribution of Arab countries to familial mediterranean fever research: a pubmed-based bibliometric analysis. Rheumatol Int. https://doi.org/10.1007/s00296-021-04852-0CrossRefPubMedPubMedCentral

Lauper K, Bijlsma JW, Burmester GR (2021) Trajectories of COVID-19 information in the Annals of the rheumatic diseases: the first months of the pandemic. Ann Rheum Dis 80(1):26–30. https://doi.org/10.1136/annrheumdis-2020-219217CrossRefPubMed

(2021) https://www.elsevier.com/__data/assets/pdf_file/0017/114533/Scopus_GlobalResearch_Factsheet2019_FINAL_WEB.pdf. Accessed 26 Jul 2021

AlRyalat SAS, Malkawi LW, Momani SM (2019) Comparing bibliometric analysis using PubMed, Scopus, and Web of Science databases. JoVE 152:e58494. https://doi.org/10.3791/58494CrossRef

10.

Perianes-Rodriguez A, Waltman L, Van Eck NJ (2016) Constructing bibliometric networks: a comparison between full and fractional counting. J Informetrics 10(4):1178–1195. https://doi.org/10.1016/j.joi.2016.10.006CrossRef

11.

Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus EF (2020) Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79(7):859–866CrossRef

12.

McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C (2020) Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2(7):e437–e445CrossRef

13.

Tufan A, Güler AA, Matucci-Cerinic M (2020) COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 50(SI-1):620–632CrossRef

14.

Ho SO, Mak JW, Jacqueline SO, Grace LU, Frankie LU, Jolly LE, Shirley CH, Carmen HO, Chan JM, Shing-Pak KO, Woon-Leung NG (2020) Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: a population-based study. Semin Arthritis Rheum 50(5):885–889. https://doi.org/10.1016/j.semarthrit.2020.07.012CrossRefPubMedPubMedCentral

15.

Fredi M, Cavazzana I, Moschetti L et al (2020) COVID-19 in patients with rheumatic diseases in northern Italy: a single-center observational and case-control study. Lancet Rheumatol 2(9):e549–e556. https://doi.org/10.1016/S2665-9913(20)30169-7CrossRefPubMedPubMedCentral

16.

Liu M, Gao Y, Zhang Y, Shi S, Chen Y, Tian J (2020) The association between severe or death COVID-19 and autoimmune disease: a systematic review and meta-analysis. J Infect 81:e93-95CrossRef

17.

Favalli EG, Ingegnoli F, Cimaz R, Caporali R (2021) What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis 80(2):e18. https://doi.org/10.1136/annrheumdis-2020-217615CrossRefPubMed

18.

Michelena X, Borrell H, López-Corbeto M et al (2020) Incidence of COVID-19 in a cohort of adult and pediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying antirheumatic drugs. Semin Arthritis Rheum 50(4):564–570. https://doi.org/10.1016/j.semarthrit.2020.05.001CrossRefPubMedPubMedCentral

19.

Quartuccio L, Valent F, Pasut E, Tascini C, De Vita S (2020) Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine 87(5):439–443. https://doi.org/10.1016/j.jbspin.2020.05.003CrossRefPubMedPubMedCentral

20.

Hooijberg F, Boekel L, Vogelzang EH, Leeuw M, Boers M, van Vollenhoven R, Lems WF, Nurmohamed MT, Wolbink G (2020) Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. Lancet Rheumatol 2(10):e583–e585. https://doi.org/10.1016/S2665-9913(20)30286-1CrossRefPubMedPubMedCentral

21.

Wang Q, Liu J, Shao R, Han X, Su C, Lu W (2021) Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. Rheumatol Int 41(5):851–861. https://doi.org/10.1007/s00296-021-04803-9CrossRefPubMed

22.

Dejaco C, Alunno A, Bijlsma JW, Boonen A, Combe B, Finckh A, Machado PM, Padjen I, Sivera F, Stamm TA, Buttgereit F (2021) Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. Ann Rheum Dis 80(4):518–526. https://doi.org/10.1136/annrheumdis-2020-218697CrossRef

23.

Ciurea A, Papagiannoulis E, Bürki K, Von Loga I, Micheroli R, Möller B, Rubbert-Roth A, Andor M, Bräm R, Müller A, Dan D (2021) Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 80(2):238–241. https://doi.org/10.1136/annrheumdis-2020-218705CrossRefPubMed

24.

Faye AS, Lee KE, Laszkowska M, Kim J, Blackett JW, McKenney AS, Krigel A, Giles JT, Wang R, Bernstein EJ, Green PH (2021) Risk of adverse outcomes in hospitalized patients with autoimmune disease and COVID-19: a matched cohort study from New York City. J Rheumatol 48(3):454–462. https://doi.org/10.3899/jrheum.200989CrossRefPubMed

25.

FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMMEDIATE consortium and contributors (2021) Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 80(4):527–538. https://doi.org/10.1136/annrheumdis-2020-218310CrossRef

26.

Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, Gonzalez-Gay MA, Martinez-Lopez D, Castrejón I, Alvaro-Gracia JM, Fernández DF (2020) Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 79(12):1544–1549. https://doi.org/10.1136/annrheumdis-2020-218296CrossRefPubMed

27.

Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, Mateus EF, Richez C, Santos MJ, Schmajuk G, Scirè CA (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-219498CrossRefPubMed

28.

Misra DP, Agarwal V, Gasparyan AY, Zimba O (2020) Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 39:2055–2062. https://doi.org/10.1007/s10067-020-05073-9CrossRefPubMed

29.

Ramirez GA, Gerosa M, Beretta L, Bellocchi C, Argolini LM, Moroni L, Della Torre E, Artusi C, Nicolosi S, Caporali R, Bozzolo EP (2020) COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients. Semin Arthritis Rheum 50(5):1150–1157. https://doi.org/10.1016/j.semarthrit.2020.06.012CrossRefPubMedPubMedCentral

30.

Cardoso EM, Hundal J, Feterman D, Magaldi J (2020) Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology. Clin Rheumatol 39:2811–2815. https://doi.org/10.1007/s10067-020-05310-1CrossRef

31.

Gracia-Ramos AE, Saavedra-Salinas MÁ (2021) Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review. Rheumatol Int 41:799–809. https://doi.org/10.1007/s00296-021-04794-7CrossRefPubMed

32.

Shah S, Danda D, Kavadichanda C, Das S, Adarsh MB, Negi VS (2020) Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment. Rheumatol Int 40(10):1539–1554. https://doi.org/10.1007/s00296-020-04639-9CrossRefPubMed

33.

Mariano RZ, Rio AP, Reis F (2020) Covid-19 overlapping with systemic sclerosis. Rev Soc Bras Med Tro. https://doi.org/10.1590/0037-8682-0450-2020CrossRef

34.

Ferri C, Giuggioli D, Raimondo V, Dagna L, Riccieri V, Zanatta E, Guiducci S, Tavoni A, Foti R, Cuomo G, De Angelis R (2021) COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. Lancet Rheumatol 3(3):e166–e168. https://doi.org/10.1016/S2665-9913(21)00007-2CrossRefPubMedPubMedCentral

35.

Matucci-Cerinic M, Bruni C, Allanore Y et al (2020) Systemic sclerosis and the COVID-19 pandemic: world scleroderma Foundation preliminary advice for patient management. Ann Rheum 79:S724–S726. https://doi.org/10.1136/annrheumdis-2020-217407CrossRef

36.

McGonagle D, Bridgewood C, Ramanan AV, Meaney JF, Watad A (2021) COVID-19 vasculitis and novel vasculitis mimics. Lancet Rheumatol 3(3):224–233. https://doi.org/10.1016/S2665-9913(20)30420-3CrossRef

37.

Özdemir B, Erden A, Güven SC, Armagan B, Apaydin H, Karakas Ö, Akdag AG, Ates İ, Kucuksahin O, Omma A (2021) COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis? Rheumatol Int 41:1515–1521. https://doi.org/10.1007/s00296-021-04896-2CrossRefPubMed

38.

Qurratulain Q, Ahmed A, Jones Q (2021) Lesson of the month: Severe granulomatosis with polyangiitis (GPA): a diagnostic challenge during the COVID-19 pandemic. Clin Med (Lond) 21(1):79–80. https://doi.org/10.7861/clinmed.2020-0793CrossRef

39.

Halpin S, O’Connor R, Sivan M (2021) Long COVID and chronic COVID syndromes. J Med Virol 93(3):1242–1243. https://doi.org/10.1002/jmv.26587CrossRefPubMed

40.

Wilson C (2020) Concern coronavirus may trigger post-viral fatigue syndromes. New Sci 246(3278):10–11. https://doi.org/10.1016/S0262-4079(20)30746-6CrossRefPubMedPubMedCentral

41.

Galeotti C, Bayry J (2020) Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol 16:413–414. https://doi.org/10.1038/s41584-020-0448-7CrossRef

42.

Jacobs J (2021) Persistent SARS-2 infections contribute to long COVID-19. Med Hypotheses 149:110538. https://doi.org/10.1016/j.mehy.2021.110538CrossRefPubMedPubMedCentral

43.

Wang JY, Zhang W, Roehrl MW, Roehrl VB, Roehrl MH (2021) An autoantigen profile of human A549 lung cells reveals viral and host etiologic molecular attributes of autoimmunity in COVID-19. J Autoimmun 120:102644. https://doi.org/10.1016/j.jaut.2021.102644CrossRefPubMedPubMedCentral

44.

Bonometti R, Sacchi M, Stobbione P et al (2020) The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Eur Rev Med Pharmacol Sci 24(18):9695–9697. https://doi.org/10.26355/eurrev_202009_23060CrossRefPubMed

45.

Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, Angoulvant F, Debray A, Basmaci R, Salvador E, Biscardi S, Frange P (2020) Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ 369:m2094. https://doi.org/10.1136/bmj.m2094CrossRefPubMedPubMedCentral

46.

Selvaraj V, Moustafa A, Dapaah-Afriyie K, Birkenbach MP (2021) COVID-19-induced granulomatosis with polyangiitis. BMJ Case Reports CP 14(3):e242142. https://doi.org/10.1136/bcr-2021-242142CrossRef

47.

Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR et al (2021) American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases—version 1. Arthritis Rheumatol 73(7):1093–1107. https://doi.org/10.1002/art.41734CrossRefPubMedPubMedCentral

48.

Park JK, Lee EB, Shin K, Sung YK, Kim TH, Kwon SR, Lee MS, Hong SJ, Choi BY, Lee SS, Back HJ (2021) COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: clinical guidance of the Korean College of Rheumatology. J Korean Med Sci 36(12):e95. https://doi.org/10.3346/jkms.2021.36.e95CrossRefPubMedPubMedCentral

49.

Santosa A, Xu C, Arkachaisri T, Kong KO, Lateef A, Lee TH, Leong KH, Low AHL, Sriranganathan MK, Tan TC, Teng GG (2021) Recommendations for COVID-19 vaccination in people with rheumatic disease: developed by the Singapore Chapter of Rheumatologists. Int J Rheum Dis 24(6):746–757. https://doi.org/10.1111/1756-185X.14107CrossRefPubMedPubMedCentral

50.

Society, The Greek Rheumatology, and Professional Association of Rheumatologists (2020) Vaccination against SARS-CoV-2 in immunosuppressed patients with rheumatic diseases: position statement of the Greek Rheumatology Society. Mediterr J Rheumatol 31(4):430–432. https://doi.org/10.31138/mjr.31.4.430CrossRef

51.

Ferretti F, Cannatelli R, Benucci M, Carmagnola S, Clementi E, Danelli P, Dilillo D, Fiorina P, Galli M, Gallieni M, Genovese G (2021) How to manage COVID-19 vaccination in immune-mediated inflammatory diseases: an expert opinion by IMIDs Study Group. Front Immunol 12:1206. https://doi.org/10.3389/fimmu.2021.656362CrossRef

52.

Tang W, Askanase AD, Khalili L, Merrill JT (2021) SARS-CoV-2 vaccines in patients with SLE. Lupus Sci Med 8(1):e000479. https://doi.org/10.1136/lupus-2021-000479CrossRefPubMed

53.

Watad A, De Marco G, Mahajna H, Druyan A, Entity M, Hijazi N, Haddad A, Elias M, Zisman D, Naffaa ME, Brodavka M (2021) Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines 9(5):435. https://doi.org/10.3390/vaccines9050435CrossRefPubMedPubMedCentral

54.

Terracina KA, Tan FK (2021) Flare of rheumatoid arthritis after COVID-19 vaccination. Lancet Rheumatol 3(7):e469–e470. https://doi.org/10.1016/S2665-9913(21)00108-9CrossRefPubMedPubMedCentral

55.

An QJ, Qin DA, Pei JX (2021) Reactive arthritis after COVID-19 vaccination. Hum Vaccin Immunother. https://doi.org/10.1080/21645515.2021.1920274CrossRefPubMed

56.

Flowers RC, Rivera Rodriguez B, Corbitt K (2021) Streptococcus Gordonii septic arthritis of the glenohumeral joint following deltoid intramuscular vaccination. BMJ Case Rep 14(5):e243066. https://doi.org/10.1136/bcr-2021-243066CrossRefPubMed

57.

Wade SD, Kyttaris VC (2021) Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study. Rheumatol Int 41(6):1115–1124. https://doi.org/10.1007/s00296-021-04847-xCrossRefPubMed

58.

Spiera R, Jinich S, Jannat-Khah D (2021) Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-220604CrossRefPubMed

59.

Haberman RH, Herati R, Simon D, Samanovic M, Blank RB, Tuen M, Koralov S, Atreya R, Tascilar K, Allen J, Castillo R (2021) Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-220597CrossRefPubMed

60.

Yurttas B, Poyraz BC, Sut N, Ozdede A, Oztas M, Uğurlu S, Tabak F, Hamuryudan V, Seyahi E (2021) Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey. Rheumatol Int 41(6):1105–1114. https://doi.org/10.1007/s00296-021-04841-3CrossRefPubMed

61.

Felten R, Dubois M, Ugarte-Gil MF, Chaudier A, Kawka L, Bergier H, Costecalde C, Pijnenburg L, Fort J, Chatelus E, Sordet C (2021) Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases. Lancet Rheumatol 3(4):e243–e245. https://doi.org/10.1016/S2665-9913(21)00039-4CrossRefPubMedPubMedCentral

62.

Fragoulis GE, Grigoropoulos I, Mavrea E, Arida A, Bournia VK, Evangelatos G, Fragiadaki K, Karamanakos A, Kravvariti E, Panopoulos S, Pappa M (2021) Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: a cross-sectional study. Rheumatol Int 41(5):895–902. https://doi.org/10.1007/s00296-021-04817-3CrossRefPubMed

63.

Zanettini C, Omar M, Dinalankara W, Imada EL, Colantuoni E, Parmigiani G, Marchionni L (2021) Influenza vaccination and covid-19 mortality in the USA: an ecological study. Vaccines 9(5):427. https://doi.org/10.3390/vaccines9050427CrossRefPubMedPubMedCentral

64.

Smeele HT, Perez-Garcia LF, Grimminck K, Schoenmakers S, Mulders AG, Dolhain RJ (2021) Systemic lupus erythematosus and COVID-19 during pregnancy. Lupus 30(7):1188–1191. https://doi.org/10.1177/09612033211002270CrossRefPubMedPubMedCentral

65.

Boyadzhieva VV, Stoilov NR, Stoilov RM (2020) Coronavirus disease 2019 (COVID-19) during pregnancy in patients with rheumatic diseases. Rheumatol Int 40(11):1753–1762. https://doi.org/10.1007/s00296-020-04698-yCrossRefPubMed

66.

Scioscia M, Praino E, Scioscia C (2020) Rheumatic diseases during pregnancy and SARS-CoV-2: an appeal for medication adherence. Int J Gynecol Obstet 150(2):269–270. https://doi.org/10.1002/ijgo.13255CrossRef

67.

Kwak-Kim J, Ota K, Sung N, Huang C, Alsubki L, Lee S, Han JW, Han A, Yang X, Saab W, Derbala Y (2020) COVID-19 and immunomodulation treatment for women with reproductive failures. J Reprod Immunol 141:103168. https://doi.org/10.1016/j.jri.2020.103168CrossRefPubMedPubMedCentral

68.

Ramoni VL, Xoxi B, Beneventi F, Bellingeri C, Montecucco C, Spinillo A (2020) Efficacy of a screening strategy for the detection of rheumatic diseases in early pregnancy during COVID-19 pandemic. Lupus 29(13):1821–1823. https://doi.org/10.1177/0961203320952848CrossRefPubMed

69.

Naveen R, Sundaram TG, Agarwal V, Gupta L (2021) Teleconsultation experience with the idiopathic inflammatory myopathies: a prospective observational cohort study during the COVID-19 pandemic. Rheumatol Int 41(1):67–76. https://doi.org/10.1007/s00296-020-04737-8CrossRefPubMed

70.

Bos WH, van Tubergen A, Vonkeman HE (2021) Telemedicine for patients with rheumatic and musculoskeletal diseases during the COVID-19 pandemic; a positive experience in the Netherlands. Rheumatol Int 41(3):565–573. https://doi.org/10.1007/s00296-020-04771-6CrossRefPubMed

71.

So H, Szeto CC, Tam LS (2021) Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak. Ann Rheum Dis 80(6):e97–e97. https://doi.org/10.1136/annrheumdis-2020-218220CrossRef

72.

Kernder A, Morf H, Klemm P et al (2021) Digital rheumatology in the era of COVID-19: results of a national patient and physician survey. RMD Open 7:e001548. https://doi.org/10.1136/rmdopen-2020-001548CrossRefPubMed

73.

Howren A, Aviña-Zubieta JA, Rebić N, Dau H, Gastonguay L, Shojania K, Davidson E, De Vera MA (2020) Virtual rheumatology appointments during the COVID-19 pandemic: an international survey of perspectives of patients with rheumatic diseases. Clin Rheumatol 39(11):3191–3193. https://doi.org/10.1007/s10067-020-05338-3CrossRefPubMed

74.

López-Medina C, Escudero A, Collantes-Estevez E (2021) COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases. Ann Rheum Dis 80(4):e50–e50. https://doi.org/10.1136/annrheumdis-2020-218008CrossRef

75.

Chevallard M, Belloli L, Ughi N, Adinolfi A, Casu C, Di Cicco M, Filippini DA, Muscarà M, Schito E, Verduci E, Gentile MG (2021) Use of telemedicine during the COVID-19 pandemic in patients with inflammatory arthritis: a retrospective study on feasibility and impact on patient-reported outcomes in a real-life setting. Rheumatol Int 41(7):1253–1261. https://doi.org/10.1007/s00296-021-04863-xCrossRefPubMed

76.

Palmer JL, Siddle HJ, Redmond AC, Alcacer-Pitarch B (2021) Implementation of podiatry telephone appointments for people with rheumatic and musculoskeletal diseases. J Foot Ankle Res 14:4. https://doi.org/10.1186/s13047-020-00441-9CrossRefPubMedPubMedCentral

77.

Morf H, Krusche M, Knitza J (2021) Patient self-sampling: a cornerstone of future rheumatology care? Rheumatol Int 41(6):1187–1188. https://doi.org/10.1007/s00296-021-04853-zCrossRefPubMedPubMedCentral

78.

Qu Y, Brady K, Apilado R et al (2017) Capillary blood collected on volumetric absorptive microsampling (VAMS) device for monitoring hydroxychloroquine in rheumatoid arthritis patients. J Pharm Biomed Anal 140:334–341. https://doi.org/10.1016/j.jpba.2017.03.047CrossRefPubMed

79.

Bilal S, Shanmugam VK (2021) Enhancing rheumatology education during the COVID-19 pandemic. Rheumatol Int 41:503–508. https://doi.org/10.1007/s00296-020-04769-0CrossRefPubMed

80.

Dua AB, Kilian A, Grainger R, Fantus SA, Wallace ZS, Buttgereit F, Jonas BL (2020) Challenges, collaboration, and innovation in rheumatology education during the COVID-19 pandemic: leveraging new ways to teach. Clin Rheumatol 39:3535–3541. https://doi.org/10.1007/s10067-020-05449-xCrossRefPubMed

81.

Ahmed S, Zimba O, Gasparyan AY (2020) Moving towards online rheumatology education in the era of COVID-19. Clin Rheumatol 39:3215–3222. https://doi.org/10.1007/s10067-020-05405-9CrossRefPubMed

82.

Ahmed S, Zimba O, Gasparyan AY (2020) Diversifying online rheumatology education options in the era of COVID-19. Clin Rheumatol 39(12):3533–3534. https://doi.org/10.1007/s10067-020-05468-8CrossRefPubMed

83.

Shaw SCK (2020) Hopelessness, helplessness, and resilience: the importance of safeguarding our trainees’ mental wellbeing during the COVID-19 pandemic. Nurse Educ Pract 44:102780–102780CrossRef

84.

Doskaliuk B, Zimba O, Yatsyshyn R, Kovalenko V (2020) Rheumatology in Ukraine. Rheumatol Int 40(2):175–182. https://doi.org/10.1007/s00296-019-04504-4CrossRefPubMed

85.

Najm A, Alunno A, Sivera F, Ramiro S, Haines C (2020) Working Group on Training in Rheumatology across Europe. Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study. RMD Open 6(2):e001183. https://doi.org/10.1136/rmdopen-2020-001183CrossRefPubMedPubMedCentral

86.

Fragoulis GE, Evangelatos G, Arida A et al (2020) Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. Ann Rheum Dis 80(4):e60–e60. https://doi.org/10.1136/annrheumdis-2020-217935CrossRef

87.

Khabbazi A, Kavandi H, Paribanaem R et al (2020) Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-218756CrossRefPubMed

88.

Michaud K, Wipfler K, Shaw Y, Simon TA, Cornish A, England BR, Ogdie A, Katz P (2020) Experiences of patients with rheumatic diseases in the United States during early days of the COVID-19 pandemic. ACR Open Rheumatol 2(6):335–343. https://doi.org/10.1002/acr2.11148CrossRefPubMedPubMedCentral

89.

Pineda-Sic RA, Galarza-Delgado DA, Serna-Peña G, Castillo-Torres SA, Flores-Alvarado DE, Esquivel-Valerio JA, Hernández-Galarza IDJ (2021) Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience. Ann Rheum Dis 80(6):e85–e85. https://doi.org/10.1136/annrheumdis-2020-218198CrossRef

90.

Durcan G, Barut K, Haslak F, Doktur H, Yildiz M, Adrovic A, Sahin S, Kasapcopur O (2021) Psychosocial and clinical effects of the COVID-19 pandemic in patients with childhood rheumatic diseases and their parents. Rheumatol Int 41(3):575–583. https://doi.org/10.1007/s00296-021-04790-xCrossRefPubMed

91.

Bhatia A, Manish KC, Gupta L (2021) Increased risk of mental health disorders in patients with RA during the COVID-19 pandemic: a possible surge and solutions. Rheumatol Int 41:843–850. https://doi.org/10.1007/s00296-021-04829-zCrossRefPubMed

92.

Matcham F, Ali S, Irving K et al (2016) Are depression and anxiety associated with disease activity in rheumatoid arthritis? A prospective study BMC prospective study. BMC Musculoskelet Disord 17:155. https://doi.org/10.1186/s12891-016-1011-1CrossRefPubMedPubMedCentral

Title: COVID-19 from a rheumatology perspective: bibliometric and altmetric analysis
Authors: Bohdana Doskaliuk
Roman Yatsyshyn
Iryna Klishch
Olena Zimba
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Systemic Lupus Erythematosus
Systemic Sclerosis
COVID-19
Published in: Rheumatology International / Issue 12/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-021-04987-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2021

The stratification of primary Sjogren’s syndrome: is it really solving the problem?

YouTube as a source of information on COVID-19 vaccination in rheumatic diseases

Changing trends in rheumatoid arthritis mortality in Mexico, from 1998 to 2017

Association of extended myositis panel results, clinical features, and diagnoses: a single-center retrospective observational study

Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study

Emerging epigenetic targets in rheumatoid arthritis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage